Kyowa Hakko Kirin completes $70m mAb manufacturing plant in Japan

By Dan Stanton

- Last updated on GMT

Image c/o Kyowa Hakko Kirin
Image c/o Kyowa Hakko Kirin

Related tags Monoclonal antibodies

Kyowa Hakko Kirin has completed construction on a ¥7.1bn mammalian cell-based manufacturing plant in Japan equipped with a 12,000L bioreactor.

The HB6 plant in Takasaki city – about 100km north-west of Tokyo – will begin manufacturing a number of active pharmaceutical ingredients later this year, with commercial production for the Japanese, US and European markets set to commence in 2019.

The 4,000m2​ facility cost around ¥7.1bn ($70m) and is equipped with a 12,000 L bioreactor which the firm says is one of the largest of its kind in Japan.

The plant will focus on monoclonal antibodies, but the firm has not revealed which products in its pipeline may be made there.

The firm’s lead is brodalumab, a mAb being developed with Amgen for Psoriasis, approved in Japan, but there are also several mAbs in the Phase III stage, including benralizumab being co-developed with AstraZeneca to target asthma.

Completion of the plant had originally been set for April this year, but Kyowa Hakko Kirin did not respond to this publication when contacted as to why there was a delay.

In April 2014​, the firm completed construction of the HA4 plant at the Takasaki site. The plant is of comparable size to the HB6 facility and also boasts a 12,000L stainless steel bioreactor.

Related news

Related products

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers